Category Archives: Psoriasis

UVB NARROWBAND UNITS - Treat psoriasis at home. SKIN MATTERS BRISTOL
UVB NARROWBAND - For treatment of Psoriasis and other skin conditions. Welcome to Skin Matters Bristol. We supply UVB Narrowband Units across the UK, deliver...

By: paul bristol

More:
UVB NARROWBAND UNITS - Treat psoriasis at home. SKIN MATTERS BRISTOL - Video

Public release date: 19-Mar-2013 [ | E-mail | Share ]

Contact: Andrew Lavin andrewlavin@alavin.com 516-944-4486 American Associates, Ben-Gurion University of the Negev

BEER-SHEVA, Israel, March 20, 2013 -- Ben-Gurion University of the Negev (BGU) researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis. The finding was reported in a new paper published in Chemistry and Biology.

Psoriasis is a chronic, non-contagious disease characterized by inflamed lesions covered with silvery-white scabs of dead skin. An auto-immune disease, psoriasis affects at least four million Americans. It is caused by the disturbance in the natural balance between pro-inflammatory signals and signals that inhibit inflammation.

One of the key signals involved in the progression of psoriasis is the immune system protein Interleukin 17 (IL-17). The research team developed a method to inhibit IL-17 pro-inflammatory signals and proved that their engineered receptor, IL-17R, is highly effective in reducing IL-17 induced inflammatory signals in mice models. Moreover, injection of the receptor into a mouse model with acute human psoriasis eliminated the symptoms, essentially curing the disease.

"Using directed evolution to improve the properties of the IL-17 receptor, we have created engineered mutants that might prove there is a viable treatment for patients with severe psoriasis that do not respond to current drugs," explains Dr. Amir Aharoni, one of the researchers in BGU's Department of Life Sciences and the National Institute for Biotechnology in the Negev.

"Since the directed evolution method can be applied to other receptors involved in autoimmune diseases and cancer, I believe that we are just starting to unravel the potential of this approach," Aharoni adds.

Directed evolution is an iterative Darwinian optimization process used in protein engineering whereby the fittest variants are selected from a collection of random mutations. Improved variants are identified and isolated by screening or selection for the property of interest. This approach is particularly advantageous in cases in which no prior knowledge of a protein's mechanism and structure is available.

The other researchers credited in "Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model" are BGU's Dr. Marianna Zaretsky and Teva researchers Dr. Liora Sklair-Tavron, Dr. Joel Kaye and Revital Etzyoni.

###

Follow this link:
Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug

Ben-Gurion University of the Negev (BGU) researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis. The finding was reported in a new paper published in Chemistry and Biology.

Psoriasis is a chronic, non-contagious disease characterized by inflamed lesions covered with silvery-white scabs of dead skin. An auto-immune disease, psoriasis affects at least four million Americans. It is caused by the disturbance in the natural balance between pro-inflammatory signals and signals that inhibit inflammation.

One of the key signals involved in the progression of psoriasis is the immune system protein Interleukin 17 (IL-17). The research team developed a method to inhibit IL-17 pro-inflammatory signals and proved that their engineered receptor, IL-17R, is highly effective in reducing IL-17 induced inflammatory signals in mice models. Moreover, injection of the receptor into a mouse model with acute human psoriasis eliminated the symptoms, essentially curing the disease.

"Using directed evolution to improve the properties of the IL-17 receptor, we have created engineered mutants that might prove there is a viable treatment for patients with severe psoriasis that do not respond to current drugs," explains Dr. Amir Aharoni, one of the researchers in BGU's Department of Life Sciences and the National Institute for Biotechnology in the Negev.

"Since the directed evolution method can be applied to other receptors involved in autoimmune diseases and cancer, I believe that we are just starting to unravel the potential of this approach," Aharoni adds.

Directed evolution is an iterative Darwinian optimization process used in protein engineering whereby the fittest variants are selected from a collection of random mutations. Improved variants are identified and isolated by screening or selection for the property of interest. This approach is particularly advantageous in cases in which no prior knowledge of a protein's mechanism and structure is available.

The other researchers credited in "Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model" are BGU's Dr. Marianna Zaretsky and Teva researchers Dr. Liora Sklair-Tavron, Dr. Joel Kaye and Revital Etzyoni.

Journal reference: Chemistry & Biology

Provided by American Associates, Ben-Gurion University of the Negev

View original post here:
Team develops psoriasis drug

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ --

Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor.

(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )

The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of VBY-891 in healthy adults.

"The initiation of this Phase 1 trial represents a significant development objective for Virobay's collaboration with LEO Pharma," stated Robert Booth, Ph.D., Chief Executive Officer of Virobay. "Virobay has plans to initiate clinical studies with additional cathepsin inhibitors during 2013 as we seek to develop new therapies for underserved diseases. Published prelinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with dermatological disorders such as psoriasis. In addition, our own preclinical data with selective cathepsin S inhibitors has demonstrated efficacy in models of both psoriasis and atopic dermatitis," stated Robert Booth. "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-891."

"Reaching this important milestone in our collaboration with Virobay brings us one step closer to provide an oral treatment for psoriasis patients. We believe that VBY-891 has the potential to provide an oral treatment that may alleviate symptoms of psoriasis. LEO Pharma strives to constantly expand and improve treatment options for patients and this is an important example of our commitment to meeting patient needs. To the best of our knowledge, the VBY-891 compound has the potential to be the first in class on the market," said Kim Kjller, Senior Vice President, Global Development, LEO Pharma.

Background

About Cathepsin S and VBY-891

Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes the final proteolytic step in the processing of invariant chain in specific antigen presenting cells. This step is essential in the maturation and loading of MHC Class II with antigenic peptides and subsequent activation of CD4+ T cells. Continuous presentation of antigenic self-peptides is thought to be involved in the maintenance of chronic disease in autoimmune disorders, including psoriasis. Inhibition of cathepsin S is likely to result in a reduction in antigen presentation without an impact on innate immunity.

VBY-891 is a next generation cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of purified cathepsin S.It has picomolar inhibitory potency against the cathepsin S enzyme and nanomolar inhibitory potency in cellular assays. VBY-891 is also highly selective against human cathepsins L, B, F and K.Sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker. VBY-891 shows potent inhibitory activity in models of autoimmunity and neuropathic pain. Therefore, inhibition of cathepsin S may have therapeutic potential across a range of dermatological conditions.

Excerpt from:
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

Traitement du PSORIASIS
Watch Later Traitement Psoriasis La Gurison dUn Cas Extrmeby purealoevera 7037 views; 424. Watch Later Traitement psoriasis 10 solutions naturels contre le stressby Labosmascareignes 5818 views; 202. Watch Later Traitement naturel psoriasis acn eczma Sylvie Mliet raconte lhistoire des Labosby Labosmascareignes 13479 views; 131. Watch Later Traitement naturel efficace contre psoriasis et eczma Utilisation des soins Pso Naturaby Labosmascareignes 9103 views; 116. Watch Later ...

By: Best Line

See the article here:
Traitement du PSORIASIS - Video

FameFlynet

Kim Kardashian was spotted with more splotches on her legs when she stepped out in a white skirt on March 12 in Los Angeles. With her skin breaking out more than normal halfway through her pregnancy,Dr. Bruce Katz, director of Juva Skin and Laser Center, reveals the cause of her troublesome condition!

Kim K has been candid about her skin condition, and has even detailed the flare-ups on her showKeeping Up with the Kardashians.But now that shes halfway through her pregnancy with boyfriend Kanye Wests baby, it could be making the problem worse.

Psoriasis can be activated on any major change on the system, from stress and scratching, Dr. Katz tells HollywoodLife.com EXCLUSIVELY. He added that pregnancy, with its changes in hormones and blood circulation, can cause a flare up.

Even if Kims chronic immune diseaseare bothering her, its likely she cant get treatment while shes pregnant, Dr. Howard Sobel,Manhattan Dermatologist, Dermatologic Surgeon, tells HollywoodLife.com EXCLUSIVELY.

Since Kim is pregnant, she has most likely been told to not use the commonpsoriasistreatment cortisone, which is applied to the skin.

She may have been instructed to not use it regularly, or not use it at all since she is pregnant, said Dr. Sobel says. He adds that the corticosteroidwould get into the blood stream and affect the baby. Pregnant women should lower medication or if they could, avoid it.

Most likely, her OBGYN would have her lay off the chemicals as much as possible, he says.

Not only is Kim pregnant she has been dealing with a lot of external stress, and was even rushed to her doctors office following a frightening plane ride from Paris to Los Angeles.

The stress in general could have flared up psoriasis, and obviously the stress from a pregnancy can cause emotional stress, Dr. Sobel says.

Read this article:
Kim Kardashian’s Pregnancy Stress Making Her Psoriasis Worse –Experts

Skin Sense - Lupus Psoriasis
Host, Jeannine Mazurkiwecz, dermatologist Dr. Stephen Schleicher talk with 2 of his patients that have psoriasis and lupus.

By: ssptvvod

Originally posted here:
Skin Sense - Lupus

What Is Psoriasis?
Consultant Dermatologist and Dermatological Surgeon, Dr Nisith Sheth, answers some of these questions: 1. What is Psoriasis? 2. What causes Psoriasis and who...

By: Askimo T.V

Read more:
What Is Psoriasis? - Video

Natural Remedies for Dermatitis, Psoriasis, and Eczema
http://www.holistichealthactivation.com/ --------------------------------------------------------- ...

By: Rob Stuart

Continue reading here:
Natural Remedies for Dermatitis, Psoriasis, and Eczema - Video

traitement psoriasis
Traitement psoriasis 10 solutions naturels contre le stressby Labosmascareignes 5711 views; 244. Watch Later Symptoms of Psoriasis what is psoriasisby katywilson101 1081 views; 202. Watch Later Traitement naturel psoriasis acn eczma Sylvie Mliet raconte lhistoire des Labosby Labosmascareignes 13397 views; 131. Watch Later Traitement naturel efficace contre psoriasis et eczma Utilisation des soins Pso Naturaby Labosmascareignes 8966 views; 116. Watch Later Traitement naturel et ...

By: said rachidia

Go here to read the rest:
traitement psoriasis - Video